A completed phase 2b trial in T1D is the ‘Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (DIABIL-2)’, which is a double-blind randomised placebo-controlled age-stratified (7–35 years old) multicentre European trial assessing efficacy and safety of recombinant human IL-2 in 138 recently-diagnosed T1D patients (NCT02411253). Here, IL2 is linked to type 1 diabetes mellitus.